MD Anderson Research Highlights for February 7, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Stay updated with breaking news from Nicholas Short. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support collaborative research teams working to discover novel molecular targets to eradicate minimal residual disease in acute myeloid leukemia (AML) and to treat clonal hematopoiesis, a precursor to AML.
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.
Combination ponatinib and blinatumomab produced durable responses in patients with newly diagnosed Ph+ ALL in a phase 2 trial.
Evidence suggests newer less-intensive options have better outcomes